在感染埃博拉病毒的啮齿动物体内，法匹拉韦（T-705）的细胞内转化及其体内剂量反应。
Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus.
机构信息
US Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Ft. Detrick, MD 21702, USA.
US Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Ft. Detrick, MD 21702, USA; Currently of FUJIFILM Pharmaceuticals U.S.A., Inc., One Post Office Square, Boston, MA 02109, USA.
出版信息
Antiviral Res. 2018 Mar;151:50-54. doi: 10.1016/j.antiviral.2017.12.020. Epub 2017 Dec 28.
During the 2013-2016 Ebola virus (EBOV) outbreak in West Africa, our team at USAMRIID evaluated the antiviral activity of a number of compounds, including favipiravir (T-705), in vitro and in mouse and nonhuman primate (NHP) models of Ebola virus disease. In this short communication, we present our findings for favipiravir in cell culture and in mice, while an accompanying paper presents the results of NHP studies. We confirmed previous reports that favipiravir has anti-EBOV activity in mice. Additionally, we found that the active form of favipiravir is generated in mice in tissues relevant for the pathogenesis of EBOV infection. Finally, we observed that protection can be achieved in mice down to 8 mg/kg/day, which is lower than the dosing regimens previously reported. An accompanying paper reports the results of treating nonhuman primates infected with EBOV or with Marburg virus with oral or intravenous favipiravir.
在 2013 年至 2016 年期间，埃博拉病毒（EBOV）在西非爆发，我们美国陆军传染病医学研究所的团队评估了许多化合物的抗病毒活性，包括法匹拉韦（T-705），在体外和感染埃博拉病毒病的小鼠和非人灵长类动物（NHP）模型中进行了评估。在这篇简短的交流文章中，我们介绍了法匹拉韦在细胞培养和小鼠中的发现，而一篇伴随的论文介绍了 NHP 研究的结果。我们证实了先前的报告，即法匹拉韦在小鼠中具有抗 EBOV 活性。此外，我们发现法匹拉韦的活性形式在与 EBOV 感染发病机制相关的小鼠组织中产生。最后，我们观察到在 8mg/kg/天的剂量下可以在小鼠中实现保护，这低于先前报道的给药方案。一篇伴随的论文报告了用口服或静脉内法匹拉韦治疗感染埃博拉病毒或马尔堡病毒的非人灵长类动物的结果。
Zotero 插件